Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. 

In 2022, SCRI formed a joint venture with US Oncology Research, and will operate under the name SCRI.

The new SCRI joint venture is a fully-integrated oncology research organization focused on expanding clinical research, accelerating drug development and increasing availability and access to clinical trials for community oncology providers and patients, including those in underserved communities.

The new joint venture is led by Dee Anna Smith as CEO, Dr. Skip Burris as President, and Dr. David Spigel as Chief Scientific Officer.

Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today.

The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the US.

CRO Services

Sarah Cannon Development Innovations is a full-service, oncology-focused contract research organization (CRO) specializing in clinical development services for early phase oncology trials. As part of SCRI, it leverages expert physician leadership to design and implement clinical trials to advance therapies and improve the lives of patients fighting cancer.

SMO Services

SCRI’s Site Management Organization (SMO) offers operational, regulatory and other centralized research support services for sites on phase I through III industry-sponsored and investigator-initiated trials. The SMO offers support services for trials across tumor types.


Genospace is a specialized data science and technology company that has developed cloud-based software to advance precision medicine in the field of oncology. From early-stage drug development to approved therapies, Genospace is the fully-integrated personalized medicine engine for SCRI. Working in concert with physicians, SMO, CRO and sponsors, Genospace’s technology translates complex biomedical data into actionable and useful insights that can help inform treatment decisions and improve patient outcomes. 

Learn more about SCRI at